ORALANCE PHARMA S.A - Product Pipeline Review - Q4 2010

Date: November 1, 2010
Pages: 40
Price:
US$ 500.00
License [?]:
Publisher: Global Markets Direct
Report type: Company Report
Delivery: E-mail Delivery (PDF)
ID: OF218857BCBEN
Leaflet:

Download PDF Leaflet

ORALANCE PHARMA S.A - Product Pipeline Review - Q4 2010
Summary

Global Market Direct’s pharmaceuticals report, “ORALANCE PHARMA S.A - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. It also gives a complete picture of the company’s future therapy areas of focus.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, primary and secondary research using Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by Global Markets Direct’s team of industry experts.

Scope

- ORALANCE PHARMA S.A - company overview including business description, key employees, and other facts.
- Review of current pipeline of ORALANCE PHARMA S.A human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, for the pharmaceutical markets across the globe.
- Product profiles for late stage and clinical stage products of ORALANCE PHARMA S.A with complete description of the product’s developmental history, mechanism of action, clinical trials, major milestones and others.
- Recent updates of the ORALANCE PHARMA S.A’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate ORALANCE PHARMA S.A’s strategic position with total access to a detailed intelligence on its product pipeline.
- Assess the growth potential of ORALANCE PHARMA S.A in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the ORALANCE PHARMA S.A’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with ORALANCE PHARMA S.A.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of ORALANCE PHARMA S.A and identify potential opportunities in those areas.
- Do deals with an understanding of the mergers and partnerships that have shaped the sector.
1 TABLE OF CONTENTS

1.1 List of Tables
1.2 list of Figures

2 INTRODUCTION
3 ORALANCE PHARMA S.A SNAPSHOT

3.1 Business Description

4 ORALANCE PHARMA S.A- RESEARCH AND DEVELOPMENT OVERVIEW

4.1 Key Therapeutic Areas

5 ORALANCE PHARMA S.A- PIPELINE REVIEW

5.1 Pipeline Products by Stage of Development
5.2 Pipeline Products-Monotherapy
5.3 Pipeline Products-Combination Treatment Modalities

6 ORALANCE PHARMA S.A PIPELINE PRODUCTS GLANCE

6.1 ORALANCE PHARMA S.A Phase II Pipeline
6.2 ORALANCE PHARMA S.A Phase I Pipeline
6.3 ORALANCE PHARMA S.A Pre-Clinical Pipeline

7 ORALANCE PHARMA S.A - DRUG PROFILES

7.1 Product
  7.1.1 Product Description
  7.1.2 Mechanism of Action
  7.1.3 R&D Progress

8 ORALANCE PHARMA S.A PIPELINE ANALYSIS

8.1 ORALANCE PHARMA S.A Pipeline Products by Therapeutic Class
8.2 ORALANCE PHARMA S.A Pipeline Products by Target
8.3 ORALANCE PHARMA S.A Pipeline by Route of Administration
8.4 ORALANCE PHARMA S.A Pipeline Products by Molecule Type

9 ORALANCE PHARMA S.A- RECENT PIPELINE UPDATES
10 ORALANCE PHARMA S.A- DORMANT PIPELINE PROJECTS

10.1 Feature on Dormant Projects

11 ORALANCE PHARMA S.A- DISCONTINUED PIPELINE PRODUCTS

11.1 Discontinued Pipeline Product Profiles
  11.1.1 Product

12 ORALANCE PHARMA S.A – FEATURED NEWS
13 ORALANCE PHARMA S.A STATEMENT

13.1 ORALANCE PHARMA S.A - Locations and Subsidiaries

14 APPENDIX

14.1 Global Markets Direct Research Methodology
14.2 Coverage
14.3 Secondary Research
14.4 Primary Research
14.5 Models
14.6 Expert Panels
14.7 Contact Us
14.8 Disclaimer

LIST OF TABLES

Table 1: ORALANCE PHARMA S.A - Key Information
Table 2: ORALANCE PHARMA S.A - Key Facts
Table 3: ORALANCE PHARMA S.A - Key Therapeutic Areas
Table 4: ORALANCE PHARMA S.A - Pipeline by Stage of Development,
Table 5: ORALANCE PHARMA S.A - Monotherapy Products in Pipeline,
Table 6: ORALANCE PHARMA S.A - Combination Treatment Modalities in Pipeline,
Table 7: ORALANCE PHARMA S.A - Phase II Pipeline,
Table 8: ORALANCE PHARMA S.A - Phase I Pipeline,
Table 9: ORALANCE PHARMA S.A - Pre-Clinical Pipeline,
Table 10: ORALANCE PHARMA S.A - Pipeline By Therapeutic Class
Table 11: ORALANCE PHARMA S.A - Pipeline By Target
Table 12: ORALANCE PHARMA S.A - Pipeline By Route of Administration
Table 13: ORALANCE PHARMA S.A - Pipeline By Molecule Type
Table 14: ORALANCE PHARMA S.A - Recent Pipeline Updates
Table 15: ORALANCE PHARMA S.A - Dormant Pipeline Projects

LIST OF FIGURES

Figure 1: ORALANCE PHARMA S.A - Research and Development Overview
Figure 2: ORALANCE PHARMA S.A - Pipeline by Stage of Development,
Figure 3: ORALANCE PHARMA S.A - Monotherapy Products in Pipeline,
Figure 4: ORALANCE PHARMA S.A - Combination Treatment Modalities in Pipeline,
Figure 5: ORALANCE PHARMA S.A - Pipeline By Therapeutic Class and Stage of Development
Figure 6: ORALANCE PHARMA S.A - Pipeline By Therapeutic Class
Figure 7: ORALANCE PHARMA S.A - Pipeline By Target and Stage of Development
Figure 8: ORALANCE PHARMA S.A - Pipeline By Target
Figure 9: ORALANCE PHARMA S.A - Pipeline By Route of Administration and Stage of Development
Figure 10: ORALANCE PHARMA S.A - Pipeline By Route of Administration
Figure 11: ORALANCE PHARMA S.A - Pipeline By Molecule Type and Stage of Development
Figure 12: ORALANCE PHARMA S.A - Pipeline By Molecule Type

COMPANIES MENTIONED

ORALANCE PHARMA S.A

Ask Your Question

ORALANCE PHARMA S.A - Product Pipeline Review - Q4 2010
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: